Acesulfame Potassium vs Sucralose: which is worse?

What is Acesulfame Potassium?

Acesulfame potassium (Ace-K) is a calorie-free synthetic sweetener approximately 200 times sweeter than sucrose. It contains a potassium atom bonded to an oxathiazinone dioxide ring structure. It is heat-stable and non-metabolized, passing through the body unchanged. Often blended with sucralose or aspartame to mask bitter aftertaste.

What is Sucralose?

Sucralose is a synthetic non-caloric sweetener made by selectively chlorinating three hydroxyl groups in sucrose (table sugar). Despite being derived from sugar, the chlorination makes it non-digestible: most passes through the body without being metabolized. It is approximately 600 times sweeter than sucrose.

Documented risks

Acesulfame Potassium: The safety database for Ace-K is considered less comprehensive than that for other sweeteners. Critics have argued that the original FDA approval studies from the 1970s-1980s were insufficient in quality and length to definitively establish long-term safety. The Center for Science in the Public Interest (CSPI) has petitioned for additional testing. Two rat studies found statistically significant increases in lung tumors (in male rats) and mammary tumors at high doses. Regulatory agencies have argued these doses far exceeded typical human exposure and attributed the tumor findings to other factors. However, the question of whether Ace-K's approval studies meet modern standards has been raised by independent researchers. A 2021 study in Cell found that Ace-K and other non-nutritive sweeteners altered gut microbiome composition and affected glucose tolerance in some human participants. Ace-K specifically was associated with changes in gut bacteria that correlated with glycemic effects. Neurological concerns: some animal studies suggest Ace-K may affect brain neurotransmitter systems. A 2013 study in PLoS ONE found that Ace-K consumption in pregnant mice altered offspring postnatal taste preference and increased weight gain, suggesting potential transgenerational effects. These findings were at doses exceeding typical human intake. Endocrine disruption potential has been raised in some in vitro studies, but comprehensive human data are lacking.

Sucralose: A 2023 study published in Nature Medicine found that sucralose-1,6-hexanediacid — a gut-derived metabolite of sucralose — enhanced T-cell immune activity in vitro. The researchers found that sucralose exposure in certain doses could potentially affect immune function. However, this was an early-stage study and its clinical implications for humans are not established. A 2021 Cell study found that sucralose and other non-nutritive sweeteners altered gut microbiome composition and glucose tolerance in human participants who were non-habitual sweetener users. The study found sucralose consumption was associated with glucose intolerance changes in some individuals, suggesting gut microbiome-mediated effects on metabolism. A 2016 study in the International Journal of Occupational and Environmental Health found sucralose consumption was associated with higher leukemia incidence in male mice at high lifetime doses. This finding prompted significant concern, though regulators noted the doses used far exceeded typical human intake. Chlorinated compounds: sucralose contains chlorine atoms in its structure. Critics have argued this makes it similar to organochlorine compounds, some of which are known carcinogens. Regulatory agencies have reviewed this and do not consider the chlorine in sucralose equivalent to organochlorine pollutants; the chlorinated positions are not metabolically active. However, high-temperature cooking with sucralose can generate chlorinated compounds. EFSA's 2017 re-evaluation concluded sucralose is safe and non-carcinogenic at its ADI of 15 mg/kg body weight. The FDA ADI of 5 mg/kg/day provides a substantial safety margin relative to typical consumer intake from Splenda use.